{"pmid":32404780,"title":"FIRST CASE OF CORONAVIRUS DISEASE 2019 IN CHILDHOOD LEUKEMIA IN CHINA.","text":["FIRST CASE OF CORONAVIRUS DISEASE 2019 IN CHILDHOOD LEUKEMIA IN CHINA.","We report the first case of coronavirus disease 2019 (COVID-19) comorbid with leukemia in a patient hospitalized in Beijing, China. The patient showed a prolonged manifestation of symptoms and a protracted diagnosis period of COVID-19. It is necessary to extend isolation time, increase the number of nucleic acid detections and conduct early symptomatic treatment for children with both COVID-19 and additional health problems.","Pediatr Infect Dis J","Zhao, Yang","Zhao, Weihong","Wang, Aibin","Qian, Fang","Wang, Sa","Zhuang, Liwei","Zhang, Fujie","Sun, Delin","Gao, Guiju","32404780"],"abstract":["We report the first case of coronavirus disease 2019 (COVID-19) comorbid with leukemia in a patient hospitalized in Beijing, China. The patient showed a prolonged manifestation of symptoms and a protracted diagnosis period of COVID-19. It is necessary to extend isolation time, increase the number of nucleic acid detections and conduct early symptomatic treatment for children with both COVID-19 and additional health problems."],"journal":"Pediatr Infect Dis J","authors":["Zhao, Yang","Zhao, Weihong","Wang, Aibin","Qian, Fang","Wang, Sa","Zhuang, Liwei","Zhang, Fujie","Sun, Delin","Gao, Guiju"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404780","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1097/INF.0000000000002742","locations":["Beijing","China","CHINA"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666950579795001345,"score":9.490897,"similar":[{"pmid":32363226,"pmcid":"PMC7194972","title":"A mild type of childhood Covid-19 - A case report.","text":["A mild type of childhood Covid-19 - A case report.","This case is about a 9-year-old child diagnosed with COVID-19, with a history of epidemiology; SARS-CoV-2 nucleic acids testing was positive, while chest CT examination was negative. The clinical classification was light. Nonetheless, isolation measures should still be taken to avoid infecting others.","Radiol Infect Dis","Yin, Xiaoping","Dong, Li","Zhang, Yu","Bian, Weilin","Li, Hongjun","32363226"],"abstract":["This case is about a 9-year-old child diagnosed with COVID-19, with a history of epidemiology; SARS-CoV-2 nucleic acids testing was positive, while chest CT examination was negative. The clinical classification was light. Nonetheless, isolation measures should still be taken to avoid infecting others."],"journal":"Radiol Infect Dis","authors":["Yin, Xiaoping","Dong, Li","Zhang, Yu","Bian, Weilin","Li, Hongjun"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363226","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jrid.2020.03.004","keywords":["covid-19","ct","child","mild","sars-cov-2"],"topics":["Case Report"],"weight":1,"_version_":1666138496001114113,"score":99.195755},{"pmid":32387061,"title":"COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE).","text":["COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE).","Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19.","Bull Cancer","Baruchel, Andre","Bertrand, Yves","Boissel, Nicolas","Brethon, Benoit","Ducassou, Stephane","Gandemer, Virginie","Halfon-Domenech, Carine","Leblanc, Thierry","Leverger, Guy","Michel, Gerard","Petit, Arnaud","Ray-Lunven, Anne-France","Rohrlich, Pierre-Simon","Schneider, Pascale","Sirvent, Nicolas","Strullu, Marion","32387061"],"abstract":["Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19."],"journal":"Bull Cancer","authors":["Baruchel, Andre","Bertrand, Yves","Boissel, Nicolas","Brethon, Benoit","Ducassou, Stephane","Gandemer, Virginie","Halfon-Domenech, Carine","Leblanc, Thierry","Leverger, Guy","Michel, Gerard","Petit, Arnaud","Ray-Lunven, Anne-France","Rohrlich, Pierre-Simon","Schneider, Pascale","Sirvent, Nicolas","Strullu, Marion"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387061","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.bulcan.2020.04.003","keywords":["acute lymphoblastic leukemia-children-adolescents","covid-19","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666428892674523137,"score":98.25401},{"pmid":32392559,"title":"Treating Leukemia in the Time of COVID-19.","text":["Treating Leukemia in the Time of COVID-19.","The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of \"exposure\" versus \"clinical infectivity,\" which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is <1-2% worldwide. With a mortality rate of 1-5% in CO-VID-19 patients in the general population and potentially of >30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods.","Acta Haematol","Paul, Shilpa","Rausch, Caitlin R","Jain, Nitin","Kadia, Tapan","Ravandi, Farhad","DiNardo, Courtney D","Welch, Mary Alma","Dabaja, Bouthaina S","Daver, Naval","Garcia-Manero, Guillermo","Wierda, William","Pemmaraju, Naveen","Montalban Bravo, Guillermo","Thompson, Philip","Verstovsek, Srdan","Konopleva, Marina","Kantarjian, Hagop","Jabbour, Elias","32392559"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of \"exposure\" versus \"clinical infectivity,\" which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is <1-2% worldwide. With a mortality rate of 1-5% in CO-VID-19 patients in the general population and potentially of >30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods."],"journal":"Acta Haematol","authors":["Paul, Shilpa","Rausch, Caitlin R","Jain, Nitin","Kadia, Tapan","Ravandi, Farhad","DiNardo, Courtney D","Welch, Mary Alma","Dabaja, Bouthaina S","Daver, Naval","Garcia-Manero, Guillermo","Wierda, William","Pemmaraju, Naveen","Montalban Bravo, Guillermo","Thompson, Philip","Verstovsek, Srdan","Konopleva, Marina","Kantarjian, Hagop","Jabbour, Elias"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392559","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1159/000508199","keywords":["acute leukemia","covid-19","chronic leukemia","myelodysplastic syndrome"],"topics":["Prevention"],"weight":1,"_version_":1666528580112220162,"score":97.08601},{"pmid":32379902,"title":"COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.","text":["COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.","Coronavirus disease 2019 (COVID-19) is a novel respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), newly discovered since December 2019(Chen et al, 2020; Guan et al, 2020; Lu et al, 2020). According to WHO situation report (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-repor ts>) on 1 April, 2020, a total of 823626 cases and over 40000 death had been documented globally, rapidly evolving into a pandemic. As reported by previous studies, patients with pre-existing health conditions are more likely to progress to severe COVID-19 pneumonia(Guan et al, 2020; Huang et al, 2020; Yang et al, 2020; Zhao et al, 2020b). Here we report a COVID-19 case with pre-existing acute lymphoblastic leukemia(ALL).","Br J Haematol","Wu, Yinlian","Lin, Heng","Xie, Qiang","Chen, Qun","Huang, Yanfang","Zhu, Yueyong","Chen, Lizhou","32379902"],"abstract":["Coronavirus disease 2019 (COVID-19) is a novel respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), newly discovered since December 2019(Chen et al, 2020; Guan et al, 2020; Lu et al, 2020). According to WHO situation report (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-repor ts>) on 1 April, 2020, a total of 823626 cases and over 40000 death had been documented globally, rapidly evolving into a pandemic. As reported by previous studies, patients with pre-existing health conditions are more likely to progress to severe COVID-19 pneumonia(Guan et al, 2020; Huang et al, 2020; Yang et al, 2020; Zhao et al, 2020b). Here we report a COVID-19 case with pre-existing acute lymphoblastic leukemia(ALL)."],"journal":"Br J Haematol","authors":["Wu, Yinlian","Lin, Heng","Xie, Qiang","Chen, Qun","Huang, Yanfang","Zhu, Yueyong","Chen, Lizhou"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379902","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16799","topics":["Case Report"],"weight":1,"_version_":1666597097282994177,"score":85.44036},{"pmid":32386019,"title":"A family outbreak of coronavirus disease 2019.","text":["A family outbreak of coronavirus disease 2019.","Although continuous outbreak of coronavirus disease 2019, it has been widely reported, there were few reports regarding family cases. We reported a group of family cluster outbreak cases confirmed in Xiangya Hospital, Central South University, China, and their clinical and image characteristics have been analyzed in order to provide reference for the prevention and early diagnosis of this disease. A total of 5 patients from one family, including 4 adults and 1 child, had a history of human contact in Wuhan, Hubei. Four adult patients showed different symptoms, including cough, fever, pharyngeal pain, and dyspnea, while the child patient had no symptoms. Laboratory examination showed no abnormality in all the patients except for slight increase in CRP in 2 patients and mild abnormal liver function index in 1 patient. The chest CT showed that all patients had abnormal images, with different degrees of manifestations.All patients were finally diagnosed by the nucleic acid test.","Zhong Nan Da Xue Xue Bao Yi Xue Ban","Luo, Weijun","Xiong, Zeng","Tang, Haixiong","Zhou, Hui","32386019"],"abstract":["Although continuous outbreak of coronavirus disease 2019, it has been widely reported, there were few reports regarding family cases. We reported a group of family cluster outbreak cases confirmed in Xiangya Hospital, Central South University, China, and their clinical and image characteristics have been analyzed in order to provide reference for the prevention and early diagnosis of this disease. A total of 5 patients from one family, including 4 adults and 1 child, had a history of human contact in Wuhan, Hubei. Four adult patients showed different symptoms, including cough, fever, pharyngeal pain, and dyspnea, while the child patient had no symptoms. Laboratory examination showed no abnormality in all the patients except for slight increase in CRP in 2 patients and mild abnormal liver function index in 1 patient. The chest CT showed that all patients had abnormal images, with different degrees of manifestations.All patients were finally diagnosed by the nucleic acid test."],"journal":"Zhong Nan Da Xue Xue Bao Yi Xue Ban","authors":["Luo, Weijun","Xiong, Zeng","Tang, Haixiong","Zhou, Hui"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386019","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.11817/j.issn.1672-7347.2020.200099","keywords":["coronavirus disease 2019","crazy-paving sign","ground-glass opacity","halo sign"],"locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666340102058541056,"score":84.5825}]}